To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

NCT00881231 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Conditions

Interventions

DRUG

Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)

DRUG

Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)

Sponsors & Collaborators

Principal Investigators

  • Gaetano Morelli, M.D. · MDS Pharma Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2004-02-29
Completion
2004-02-29

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00881231 on ClinicalTrials.gov